Robert then spent a decade at early-stage biotech companies, including Chief Medical Officer at Arakis (sold to Sosei Inc), founder and CEO at Treague, founding CEO of the University of Copenhagen spin-out Avilex Pharma and founding Chief Medical Officer of KalVista (Nasdaq: KALV).
Robert qualified in medicine from UCL. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.
Prior to their exits, Robert managed CIC's investments in Inivata (sold to NeoGenomics), Gyroscope Therapeutics (sold to Novartis), Z Factor, Morphogen-IX (each part of the roll-up with Centessa), Abcodia (sold to GenIncode) and PetMedix (sold to Zoetis). Robert manages CIC's investments in Carrick Therapeutics, CMR Surgical, Exvastat, Microbiotica, Pretzel Therapeutics, and T-Therapeutics.